Themis Medicare's Q3 FY 2025-26 Quarterly Results
- 14 Feb 2026
Result Summary
- Themis Medicare Ltd reported a 12.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 3.6%.
- Its expenses for the quarter were down by 0.8% QoQ and 5.4% YoY.
- The net profit decreased 378.7% QoQ and increased 1840.4% YoY.
- The earnings per share (EPS) of Themis Medicare Ltd stood at 1.09 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 91.42 | 81.23 | 94.83 | 12.5% | -3.6% |
Total Expenses | 85.68 | 86.41 | 90.61 | -0.8% | -5.4% |
Profit Before Tax | 4.87 | -5.19 | 4.22 | -193.8% | 15.4% |
Tax | 0.29 | 0.16 | 1.14 | 81.2% | -74.6% |
Profit After Tax | 10.09 | -3.62 | 0.52 | -378.7% | 1840.4% |
Earnings Per Share | 1.09 | -0.39 | 0.06 | -379.5% | 1716.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Themis Medicare Ltd is a pharmaceutical company primarily engaged in the development, manufacturing, and marketing of a range of pharmaceutical products. The company operates within the healthcare industry, focusing on areas such as anti-tuberculosis, anti-malarial, and other therapeutic segments. Themis Medicare has been known for its commitment to research and development, continually seeking to enhance its product offerings and expand its market presence. Recent developments have included efforts to increase production capacity and expand its reach in domestic and international markets. However, detailed information about any specific recent major developments is not available in the provided data.
Revenue
In Q3FY26, Themis Medicare Ltd reported a total income of ₹91.42 crores, which represents a 12.5% increase from the previous quarter (Q2FY26) where the total income was ₹81.23 crores. This also indicates a slight decrease of 3.6% when compared to the same quarter of the previous year (Q3FY25), where the total income was ₹94.83 crores. The quarter-over-quarter growth is significant and reflects an upward trend in revenue generation. However, the year-over-year comparison shows a marginal decrease, suggesting changes in revenue dynamics over the annual period.
Profitability
The company's profitability showed marked improvement in Q3FY26. Themis Medicare Ltd's profit before tax was ₹4.87 crores, a substantial turnaround from a negative result of ₹-5.19 crores in Q2FY26. This represents a quarter-over-quarter change of -193.8%. Compared to Q3FY25, where the profit before tax was ₹4.22 crores, there was a positive year-over-year increase of 15.4%. The profit after tax for Q3FY26 was ₹10.09 crores, a significant improvement from both the previous quarter's loss of ₹-3.62 crores and the profit of ₹0.52 crores in Q3FY25, with changes of -378.7% QoQ and 1840.4% YoY. The earnings per share also increased to ₹1.09 in Q3FY26 from ₹-0.39 in Q2FY26 and ₹0.06 in Q3FY25, with respective changes of -379.5% QoQ and 1716.7% YoY.
Operating Metrics
The total expenses for Q3FY26 were reported at ₹85.68 crores, showing a slight decrease of 0.8% from the previous quarter's ₹86.41 crores. Compared to Q3FY25, there was a 5.4% decline in total expenses, which were ₹90.61 crores. The tax expense increased by 81.2% quarter-over-quarter, from ₹0.16 crores in Q2FY26 to ₹0.29 crores in Q3FY26, while year-over-year, it decreased by 74.6% from ₹1.14 crores in Q3FY25. These metrics indicate changes in operational cost management and taxation, which have impacted the company's financial performance over the quarters.